NCT06509958终止2 期
A Phase Ⅱ Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Single Injection Adductor Canal Block With HR18034 for Postoperative Pain Management in Total Knee Arthroplasty
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- AUC0-72h of the NRS-A pain intensity scores.
研究概览
简要总结
Phase Ⅱ, randomized, double-blind, comparator-controlled study to evaluate the efficacy, safety and pharmacokinetics of single injection adductor canal block with HR18034 for postoperative pain management in total knee arthroplasty compared with ropivacaine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Able and willing to provide a written informed consent
- •Scheduled to undergo primary unilateral total knee arthroplasty under general anesthesia.
- •Male or female，aged ≥ 18 years
- •Body mass index (BMI) ≥ 18 kg/m2
- •American Society of Anesthesiologists (ASA) Physical Status Classification Ⅰ~Ⅲ
排除标准
- •Subjects with deformity of the involving operative limb, or other neuropathy
- •Subjects with a history of new myocardial infarction or unstable angina within 6 months prior to randomization;
- •Subjects with a history of ischemic stroke or transient ischemic attack (TIA)
- •Subjects with a history of mental system diseases and cognitive dysfunction
- •Combination of other pain conditions that may affect postoperative pain assessment
- •Persistent or recurrent nausea and/or vomiting due to other etiologies, including, but not limited to gastric outlet obstruction, hypercalcemia, or active peptic ulcer
- •Subjects with a history of deep vein thrombosis-related disease
- •Clinically significant abnormal clinical laboratory test value
- •Allergic to a drug ingredient or component
- •Use of any of medications, which affect drug metabolism or analgesia evaluation, within 5 half-lives or as specified prior to the study surgical procedure
- •History of alcohol abuse or prescription and/or illicit drug abuse
- •Pregnant or nursing women
- •No birth control during the specified period of time
- •Participated in clinical trials of other drugs (received experimental drugs)
- •The inestigators determined that other conditions were inappropriate for participation in this clinical trial
研究组 & 干预措施
Dose 1
Experimental
干预措施: HR18034 (Drug)
Dose 2
Experimental
干预措施: HR18034 (Drug)
Ropivacaine Hydrochloride Injection
Active Comparator
干预措施: Ropivacaine Hydrochloride Injection (Drug)
结局指标
主要结局
AUC0-72h of the NRS-A pain intensity scores.
时间窗: 0 to 72 hours
AUC of NRS pain intensity scores at activity (NRS-A) through 72 hours after the beginning of study drug administration.
次要结局
- Subjects' satisfaction rating(72 hours)
- Investigators' satisfaction rating(72 hours)
- Pain intensity assessed using an 12-point NRS ranging.(Baseline till 72 hours after the beginning of study drug administration)
- Proportion of subjects who used no rescue opioid analgesic.(0-24, 24-48, 48-72, 0-72 hours)
- Quadriceps muscle strength score.(Baseline till 72 hours after the beginning of study drug administration)
- Total rescue analgesic consumption.(0-24, 24-48, 48-72, 0-72 hours)
- Range of motion of the knee joint.(Baseline till 72 hours after the beginning of study drug administration)
- AUC of the NRS-A pain intensity scores.(0-24, 0-48hours)
- AUC of the NRS-R pain intensity scores.(0-24, 0-48，0-72 hours)
- AUC of NRS pain intensity scores at rest (NRS-R) for time periods 0-24, 0-48 ,0-72 hours.(0-24, 0-48 ,0-72 hours.)
- Time to the first postoperative use of rescue opioid analgesics.(0-72hours)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Phase Ⅱ Study of Adductor Canal Block With HR18034 for Postsurgical Pain ManagementTotal Knee ArthroplastyNCT05561309Shanghai Hengrui Pharmaceutical Co., Ltd.89
招募中
2 期
Phase Ⅱ Study of Intercostal Nerve Block With HR18034 for Postsurgical Pain ManagementThoracoscopic LobectomyNCT05744674Shanghai Hengrui Pharmaceutical Co., Ltd.96
已完成
2 期
Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 DiabetesNew Onset Type-1 DiabetesNCT02005848Kamada, Ltd.70
招募中
2 期
BB-101 for the Treatment of Diabetic Lower Leg and Foot UlcersDiabetic Foot UlcerNCT06383013Blue Blood Biotech Corp.96
已完成
2 期
A Study of Hemay005 in Adult With Atopic DermatitisHemay005, Atopic DermatitisNCT05769946Ganzhou Hemay Pharmaceutical Co., Ltd79